桂西壮族和汉族女性乳腺癌分子分型、临床病理特征及临床意义的比较研究-临床医学、外科学专业论文.docxVIP

I万方数据 I 万方数据 中文摘要 目的：通过对桂西壮族和汉族妇女乳腺癌组织的分子分型、临床病理及临床特征进行研究 分析，比较不同民族人群中乳腺癌的发病与病理及临床特征的异同点，为制定个体化的治 疗、估计预后及选择正确的辅助治疗方式提供科学依据。 方法：收集我院乳腺外科 2010 年 1 月至 2013 年 11 月 430 例经手术切除和病理确诊为浸润 型乳腺癌患者，根据不同种族分成壮族（Z 组）、汉族（H 组），分别为 225 例、205 例。 根据免疫组织化学结果，将两民族乳腺癌进行分子分型，分别为：luminal A 型、luminal B 型、HER-2 过表达型和三阴型，分析两民族各亚型的临床病理特征及意义。 结果：1、壮族女性乳腺癌发病的平均年龄与汉族相比具有统计学差异，壮族发病年龄＞ 60 岁的患者比例高于汉族；2、壮族与汉族女性乳腺癌在组织学分级与分子分型上均呈正 相关(P＜0.01)，在组织学分级达 3 级时，两组出现三阴型的比例均明显增高；3、壮族与汉 族女性患者月经状态、生育次数、乳腺癌临床分期、肿瘤大小、区域淋巴结转移、组织学 分型构成比、分子分型构成比、分子分型中组织学类型构成比均无统计学差异（P＞0.05）。 结论：桂西壮族与汉族女性乳腺癌患者的分子分型构成比、病理学特征无差异，但临床特 征有差异。 关键词：壮族；汉族；乳腺癌；分子分型；临床病理特征 II万方数据 II 万方数据 A comparative study on the molecular typing, clinical pathological features and clinical significance of Western Guangxi Zhuang and Han women with breast cancer Abstract Objective To study the difference on molecular typing, clinical pathological features and clinical significance of Western Guangxi Zhuang and Han women with breast cancer. Methods 430 inpatients, with 225 zhuang and 224 Han with invasive ductal carcinoma, who were admitted to hospital during January 2010 to December 2013 in The Affiliated Hospital of Youjiang medical University For nationalities, were tested by Immunohistochemistry (IHC) and fluorescence in situ hybridization(FISH). All patients were divided into four molecular typing: Luminal A, Luminal B,HER-2 Overexpression and Basal-like. The clinical pathological features and clinical significance of breast cancer with one of above molecular typing in two ethnicities were analyzed too. Results 1.There was statistically significant difference in the average age of onset times between zhuang and han patients, the proportion of zhuang patients on group of older than 60 years old was higher than han patients. It was positively correlated with histological grading and molecular typing between zhuang and han patients with breast cancer (P0.01),the proportion of Basal-like was higher in histological grading 3. There was no statistically significan